Wells Fargo Reiterates Overweight Rating on BridgeBio Pharma (BBIO)
Tweet Send to a Friend
Wells Fargo analyst Tiago Fauth reiterated an Overweight rating and $58.00 price target on BridgeBio Pharma (NASDAQ: BBIO)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
